Universidade Federal de Sergipe
Quick facts
Phase 3 pipeline
- Piroxicam-Beta-Cyclodextrin · Rheumatology / Pain Management
Piroxicam-beta-cyclodextrin is a nonsteroidal anti-inflammatory drug (NSAID) formulated with beta-cyclodextrin to improve solubility and bioavailability, inhibiting cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Universidade Federal de Sergipe portfolio CI brief
- Universidade Federal de Sergipe pipeline updates RSS
Frequently asked questions about Universidade Federal de Sergipe
What is Universidade Federal de Sergipe's pipeline?
Universidade Federal de Sergipe has 1 drugs in Phase 3, 0 in Phase 2, 1 in Phase 1. Late-stage candidates include Piroxicam-Beta-Cyclodextrin.
Related
- Sector hub: All tracked pharma companies